Skip to main content

Table 3 Comparisons of baseline blood biomarker levels between different NSCLC cohorts

From: Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Baseline Biomarker Cohort A Cohort B Cohort C P-value$
N Mean (±SD) N Mean (±SD) N Mean (±SD)
WBC (×103 cells/μL) 27 8.4 (±3.7) 35 7.5 (±2.5) 22 9.2 (±5.3) 0.750
Hemoglobulin (gram/dL) 27 12.5 (±2.0) 35 12.7 (±1.9) 22 12.8 (±1.4) 0.805
Platelet count (× 103 cells/μL) 27 305.2 (±126.6) 35 298.8 (±125.9) 21a 281.0 (±89.8) 0.884
ANC (×103 cells/μL) 27 6.1 (±3.4) 35 5.6 (±2.1) 22 6.9 (±5.1) 0.948
ALCs (×103 cells/μL) 27 1.3 (±0.8) 35 1.1 (±0.6) 22 1.2 (±0.8) 0.571
CD3 + CD4 + % 27 40.6 (±11.1) 35 45.3 (±12.7) 22 44.5 (±9.5) 0.222
CD3 + CD8 + % 27 23.9 (±9.6) 35 27.1 (±12.5) 22 26.4 (±9.5) 0.427
CD3 + % 27 65.7 (±10.3) 35 72.4 (±10.3) 22 72.3 (±8.8) 0.014
CD3 + CD4+ count (cells/μL) 27 512.9 (±282.9) 35 492.3 (±288.1) 22 598.7 (±402.9) 0.793
CD3 + CD8+ count (cells/μL) 27 318.3 (±242.3) 35 305.5 (±260.1) 22 326.7 (±189.0) 0.705
CD4/CD8 ratio 27 2.0 (±0.9) 35 2.1 (±1.3) 22 1.9 (±0.9) 0.934
CD4 plus CD8 count (cells/μL) 27 831.2 (±451.7) 35 797.8 (±431.7) 22 925.4 (±555.5) 0.831
dNLR 27 3.4 (±3.0) 35 3.2 (±1.5) 22 3.4 (±2.5) 0.668
  1. $P-values from Kruskal-Wallis tests. Bold for statistical significance
  2. aOne patient had clumped platelets